Cash Flow Statement
Growth Metrics

Ani Pharmaceuticals (ANIP) Equity Income (2024 - 2026)

Ani Pharmaceuticals' Equity Income history spans 2 years, with the latest figure at $249000.0 for Q4 2025.

  • On a quarterly basis, Equity Income rose 112.46% to $249000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 55.56% decrease, with the full-year FY2025 number at $2.8 million, down 55.56% from a year prior.
  • Equity Income hit $249000.0 in Q4 2025 for Ani Pharmaceuticals, down from $3.1 million in the prior quarter.
  • Over the last five years, Equity Income for ANIP hit a ceiling of $9.7 million in Q1 2024 and a floor of -$2.7 million in Q2 2024.